Chemotherapeutics for Toxoplasma gondii: Molecular Biotargets, Binding Modes, and Structure-Activity Relationship...

Area of Science:

• Parasitology
• Infectious Diseases
• Medicinal Chemistry
• Drug Discovery

Background:

• Toxoplasmosis, caused by *Toxoplasma gondii*, is a significant global zoonotic health concern.
• Current therapeutic options are insufficient for treating chronic latent toxoplasmosis.
• Developing novel, safe, and effective chemotherapeutics is a critical unmet medical need.

Purpose of the Study:

• To review and identify druggable molecular biotargets for *Toxoplasma gondii*.
• To explore the binding modes and structure-activity relationships of inhibitors targeting these molecules.
• To provide insights for the development of new anti-toxoplasmosis interventions.

Main Methods:

• Literature review of potential molecular targets in *Toxoplasma gondii*.
• Analysis of druggable targets, including calcium-dependent protein kinase 1, bifunctional thymidylate synthase-dihydrofolate reductase, and farnesyl diphosphate synthase.
• Examination of inhibitor binding modes and structure-activity relationships (SAR) from medicinal chemistry perspectives.

Main Results:

• Identified key molecular targets within *Toxoplasma gondii* that are amenable to drug development.
• Detailed the binding characteristics and SAR profiles of inhibitors for these targets.
• Highlighted promising avenues for medicinal chemistry-driven therapeutic strategies.

Conclusions:

• The identified molecular targets and characterized inhibitors offer a foundation for developing novel chemotherapeutics against *Toxoplasma gondii*.
• Further research into these targets and their inhibitors can lead to effective treatments for chronic toxoplasmosis.
• This review provides valuable information for advancing the discovery of interventions for this prevalent zoonotic infection.